Advertisement

Topics

A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors

2015-04-08 09:24:25 | BioPortfolio

Published on BioPortfolio: 2015-04-08T09:24:25-0400

Clinical Trials [4954 Associated Clinical Trials listed on BioPortfolio]

A Study of the Efficacy and Safety of Etrolizumab Treatment, Compared With Adalimumab and Placebo, in Inducing Disease Remission in Ulcerative Colitis Patients Who Have Not Previously Received TNF Inhibitors (Study #2)

This Phase III, double blind, placebo and active comparator controlled, multicen ter study will investigate the efficacy and safety of etrolizumab in induction o f remission in patients wi...

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Patients Who Are Naive to TNF Inhibitors

This Phase III, double blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in patients with moderately to sever...

A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors

This phase III, double blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission in patients with m...

Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies

This two-part, open-label extension (OLE) and safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate t o severe ulcerative coliti...

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

The purpose of this study is to evaluate long-term safety information of infliximab in patients who have participated in infliximab clinical studies in ulcerative colitis.

PubMed Articles [3556 Associated PubMed Articles listed on BioPortfolio]

Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy.

Approximately half of the patients with ulcerative colitis (UC) who undergo restorative proctocolectomy develop pouchitis within 10 years of surgery. Currently, there are no approved pouchitis treatm...

Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis.

Standard outpatient induction dosing of infliximab (IFX) may not be effective in hospitalized ulcerative colitis (UC) patients with higher inflammatory burden and colectomy risk. Our aim was to determ...

Acute severe ulcerative colitis treated with accelerated infliximab induction. Case report.

Acute severe ulcerative colitis (ASUC) is a potentially life-threatening condition that requires early recognition, hospitalization and adequate treatment. Currently, the use of infliximab in ulcerati...

Andecaliximab Anti-matrix Metalloproteinase-9 Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.

Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of ulcerative colitis [UC] via disruption of intestinal barrier integrity and function. A phase 2/3 combined trial was designed to e...

Infliximab as rescue treatment in a Sweet's Syndrome related to corticodependent ulcerative colitis.

Medical and Biotech [MESH] Definitions

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.

Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.

An acute form of MEGACOLON, severe pathological dilatation of the COLON. It is associated with clinical conditions such as ULCERATIVE COLITIS; CROHN DISEASE; AMEBIC DYSENTERY; or CLOSTRIDIUM ENTEROCOLITIS.

More From BioPortfolio on "A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial